These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

101 related articles for article (PubMed ID: 10096581)

  • 1. Tat toxoid as a component of a preventive vaccine in seronegative subjects.
    Gringeri A; Santagostino E; Muça-Perja M; Le Buanec H; Bizzini B; Lachgar A; Zagury JF; Rappaport J; Burny A; Gallo RC; Zagury D
    J Acquir Immune Defic Syndr Hum Retrovirol; 1999 Apr; 20(4):371-5. PubMed ID: 10096581
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A prophylactic and therapeutic AIDS vaccine containing as a component the innocuous Tat toxoid.
    Le Buanec H; Lachgar A; Bizzini B; Zagury JF; Rappaport J; Santagostino E; Muça-Perja M; Gringeri A
    Biomed Pharmacother; 1998; 52(10):431-5. PubMed ID: 9921411
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Safety and immunogenicity of HIV-1 Tat toxoid in immunocompromised HIV-1-infected patients.
    Gringeri A; Santagostino E; Muça-Perja M; Mannucci PM; Zagury JF; Bizzini B; Lachgar A; Carcagno M; Rappaport J; Criscuolo M; Blattner W; Burny A; Gallo RC; Zagury D
    J Hum Virol; 1998; 1(4):293-8. PubMed ID: 10195254
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Induction of neutralizing antibodies and Th1-polarized and CD4-independent CD8+ T-cell responses following delivery of human immunodeficiency virus type 1 Tat protein by recombinant adenylate cyclase of Bordetella pertussis.
    Mascarell L; Fayolle C; Bauche C; Ladant D; Leclerc C
    J Virol; 2005 Aug; 79(15):9872-84. PubMed ID: 16014948
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Targeting Tat and IFN(alpha) as a therapeutic AIDS vaccine.
    Gallo RC; Burny A; Zagury D
    DNA Cell Biol; 2002 Sep; 21(9):611-8. PubMed ID: 12396603
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Procedures for preparing biologically inactive, but immunogenic HIV-1 Tat protein (Tat toxoid) for human use.
    Le Buanec H; Bizzini B
    Biomed Pharmacother; 2000 Feb; 54(1):41-4. PubMed ID: 10721461
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Enhanced cellular immunity to SIV Gag following co-administration of adenoviruses encoding wild-type or mutant HIV Tat and SIV Gag.
    Zhao J; Voltan R; Peng B; Davis-Warren A; Kalyanaraman VS; Alvord WG; Aldrich K; Bernasconi D; Buttò S; Cafaro A; Ensoli B; Robert-Guroff M
    Virology; 2005 Nov; 342(1):1-12. PubMed ID: 16109434
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A combination HIV vaccine based on Tat and Env proteins was immunogenic and protected macaques from mucosal SHIV challenge in a pilot study.
    Ferrantelli F; Maggiorella MT; Schiavoni I; Sernicola L; Olivieri E; Farcomeni S; Pavone-Cossut MR; Moretti S; Belli R; Collacchi B; Srivastava IK; Titti F; Cafaro A; Barnett SW; Ensoli B
    Vaccine; 2011 Apr; 29(16):2918-32. PubMed ID: 21338681
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immunogenicity of HIV-1 IIIB and SHIV 89.6P Tat and Tat toxoids in rhesus macaques: induction of humoral and cellular immune responses.
    Richardson MW; Mirchandani J; Silvera P; Régulier EG; Capini C; Bojczuk PM; Hu J; Gracely EJ; Boyer JD; Khalili K; Zagury JF; Lewis MG; Rappaport J
    DNA Cell Biol; 2002 Sep; 21(9):637-51. PubMed ID: 12396606
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antibodies to the HIV-1 Tat protein correlated with nonprogression to AIDS: a rationale for the use of Tat toxoid as an HIV-1 vaccine.
    Zagury JF; Sill A; Blattner W; Lachgar A; Le Buanec H; Richardson M; Rappaport J; Hendel H; Bizzini B; Gringeri A; Carcagno M; Criscuolo M; Burny A; Gallo RC; Zagury D
    J Hum Virol; 1998; 1(4):282-92. PubMed ID: 10195253
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Vaccines based on the native HIV Tat protein and on the combination of Tat and the structural HIV protein variant DeltaV2 Env.
    Ensoli B; Cafaro A; Caputo A; Fiorelli V; Ensoli F; Gavioli R; Ferrantelli F; Cara A; Titti F; Magnani M
    Microbes Infect; 2005 Nov; 7(14):1392-9. PubMed ID: 16243561
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A Tat subunit vaccine confers protective immunity against the immune-modulating activity of the human immunodeficiency virus type-1 Tat protein in mice.
    Agwale SM; Shata MT; Reitz MS; Kalyanaraman VS; Gallo RC; Popovic M; Hone DM
    Proc Natl Acad Sci U S A; 2002 Jul; 99(15):10037-41. PubMed ID: 12096189
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immunization with low doses of HIV-1 tat DNA delivered by novel cationic block copolymers induces CTL responses against Tat.
    Caputo A; Gavioli R; Altavilla G; Brocca-Cofano E; Boarini C; Betti M; Castaldello A; Lorenzini F; Micheletti F; Cafaro A; Sparnacci K; Laus M; Tondelli L; Ensoli B
    Vaccine; 2003 Mar; 21(11-12):1103-11. PubMed ID: 12559787
    [TBL] [Abstract][Full Text] [Related]  

  • 14. HIV-Tat immunization induces cross-clade neutralizing antibodies and CD4(+) T cell increases in antiretroviral-treated South African volunteers: a randomized phase II clinical trial.
    Ensoli B; Nchabeleng M; Ensoli F; Tripiciano A; Bellino S; Picconi O; Sgadari C; Longo O; Tavoschi L; Joffe D; Cafaro A; Francavilla V; Moretti S; Pavone Cossut MR; Collacchi B; Arancio A; Paniccia G; Casabianca A; Magnani M; Buttò S; Levendal E; Ndimande JV; Asia B; Pillay Y; Garaci E; Monini P;
    Retrovirology; 2016 Jun; 13(1):34. PubMed ID: 27277839
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tat as one key to HIV-induced immune pathogenesis and Tat (correction of Pat) toxoid as an important component of a vaccine.
    Gallo RC
    Proc Natl Acad Sci U S A; 1999 Jul; 96(15):8324-6. PubMed ID: 10411869
    [No Abstract]   [Full Text] [Related]  

  • 16. Design and characterization of an HIV-1 Tat mutant: inactivation of viral and cellular functions but not antigenicity.
    Mayol K; Munier S; Beck A; Verrier B; Guillon C
    Vaccine; 2007 Aug; 25(32):6047-60. PubMed ID: 17604883
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Durable HIV-1 antibody and T-cell responses elicited by an adjuvanted multi-protein recombinant vaccine in uninfected human volunteers.
    Goepfert PA; Tomaras GD; Horton H; Montefiori D; Ferrari G; Deers M; Voss G; Koutsoukos M; Pedneault L; Vandepapeliere P; McElrath MJ; Spearman P; Fuchs JD; Koblin BA; Blattner WA; Frey S; Baden LR; Harro C; Evans T;
    Vaccine; 2007 Jan; 25(3):510-8. PubMed ID: 17049679
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tat-neutralizing antibodies in vaccinated macaques.
    Tikhonov I; Ruckwardt TJ; Hatfield GS; Pauza CD
    J Virol; 2003 Mar; 77(5):3157-66. PubMed ID: 12584340
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tat toxoid: its potential role as an HIV vaccine.
    Lambert J
    J Hum Virol; 1998; 1(4):249-50. PubMed ID: 10195248
    [No Abstract]   [Full Text] [Related]  

  • 20. Control of viral replication and disease onset in cynomolgus monkeys by HIV-1 TAT vaccine.
    Ensoli B; Cafaro A
    J Biol Regul Homeost Agents; 2000; 14(1):22-6. PubMed ID: 10763887
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.